{"doi":"10.15326/jcopdf.8.1.2020.0132","title":"Randomization to Omega-3 Fatty Acid Supplementation and Endothelial Function in COPD: The COD-Fish Randomized Controlled Trial","abstract":"RATIONALE: Studies suggest a pathogenic role of endothelial dysfunction in chronic obstructive lung disease (COPD). Omega-3 (n-3) polyunsaturated fatty acid (PUFA) supplementation improves endothelial function in other diseases but has not been examined in COPD. OBJECTIVE: We hypothesized that n-3 PUFA supplementation would improve systemic endothelial function in COPD. We performed a pilot randomized, placebo-controlled, double-blind, phase 2 superiority trial (NCT00835289). METHODS: Adults with moderate and severe stable COPD (79% with emphysema on computed tomography [CT]) were randomized to high-dose fish oil capsules or placebo daily for 6 months. The primary endpoint was percentage change in brachial artery flow-mediated dilation (FMD) from baseline to 6 months. Secondary endpoints included peripheral arterial tonometry, endothelial microparticles (EMPs), 6-minute walk distance, respiratory symptoms, and pulmonary function. RESULTS: =0.01). There were no significant changes in other secondary endpoints. There were 4 serious adverse events determined to be unrelated to the study (3 in the fish oil arm and 1 in the placebo arm). CONCLUSION: Randomization to n-3 PUFAs for 6 months did not change systemic endothelial function in COPD. Changes in EMPs and SGRQ suggest n-3 PUFAs might have biologic and clinical effects that warrant further investigation.","journal":"Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation","year":2020,"id":68689,"datarank":1.0115385567492146,"base_score":3.1354942159291497,"endowment":3.1354942159291497,"self_citation_contribution":0.47032413238937254,"citation_network_contribution":0.541214424359842,"self_endowment_contribution":0.47032413238937254,"citer_contribution":0.541214424359842,"corpus_percentile":null,"corpus_rank":null,"citation_count":22,"citer_count":22,"citers_with_citation_signal":18,"citers_with_endowment":18,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.96,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT00835289"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":365435,"name":"Michael A. Thomashow","orcid":null,"position":1,"is_corresponding":false},{"id":104636,"name":"Natalie Yip","orcid":"0000-0003-4863-5569","position":2,"is_corresponding":false},{"id":363976,"name":"Kristin M. Burkart","orcid":"0000-0003-0057-8905","position":3,"is_corresponding":false},{"id":363977,"name":"Christian M. Lo Cascio","orcid":"0000-0002-2163-4219","position":4,"is_corresponding":false},{"id":281843,"name":"Daichi Shimbo","orcid":"0000-0001-6302-8834","position":5,"is_corresponding":false},{"id":24685,"name":"R. Graham Barr","orcid":"0000-0001-8021-0072","position":6,"is_corresponding":false},{"id":363975,"name":"John S. Kim","orcid":"0000-0002-8887-150X","position":0,"is_corresponding":true}],"reference_count":66,"raw_metadata":null,"created_at":"2026-07-18T21:41:52.279368Z","pmid":"33150779","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}